Q4 2026
Ends Dec 31, 2026
Revenue
$0.0B
$0.0B to $0.0B
EPS
-0.66
-0.66 to -0.66
No analyst count
EPS: No analyst count
Apr 29, 04:24 PM UTC
stable/analyst-estimates
Healthcare
Live Price
Offline$4.50
+6.64% today
1Y Change
+88.28%
Window
Jun 30, 2025 → Jun 26, 2026
Coverage: 249 bars · Jun 30, 2025 → Jun 26, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
OnKure Therapeutics, Inc. (OKUR) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $4.50 and up 88.3% across the available one-year price window (Jun 30, 2025 → Jun 26, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -11.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -11.4%, free cash flow -1.4% with operating margin 0.0% and ROIC -110.9%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OKUR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
OKUR is 70.30 pts ahead over the shared 1Y window.
OKUR had 32.42 pts deeper max drawdown than SPY.
OKUR beat SPY in 2 of 2 calendar years shown and trailed in 0.
OKUR
+88.28%
Normalized return
SPY
+17.99%
S&P 500
Excess Return
+70.30 pts
Relative to SPY
OKUR Max Drawdown
-41.56%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for OKUR and SPY.
| Year | OKUR | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +52.03% | +6.71% | +45.32 pts | OKUR |
| 2025 | +19.25% | +11.19% | +8.05 pts | OKUR |
EPS Consensus
-0.66
Range -0.66 -> -0.66
No analyst count
vs prior: -4.7%Revenue Outlook
$0.0B
Range $0.0B -> $0.0B
No analyst count
vs prior: 0.0%Price Target
--
-- -> --
No analyst count
Recommendations
--
No recommendation feed
No date
Consensus Spread
Lower spread suggests tighter agreement across covering analysts.
Next Earnings
EPS --
Revenue --
No analyst count
EPS Revisions
No recent EPS revision rows
0 revision rows
Trend
Consensus average across visible periods
Trend
Average analyst revenue estimate
Timeline
Sorted by period end date. Includes both cached rows and live fallbacks from the configured analyst feed.
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.